The management of mantle cell lymphoma has evolved dramatically since 1994, when the Revised European-American Lymphoma Classification recognized it as a separate disease entity. This was based not only on the distinct molecular features (hallmark t(11;14) translocation) and immunophenotype of mantle cell lymphoma but also on its distinct clinical course, with much poorer outcomes than those of other patients with so-called indolent lymphomas.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile